

Table 1: Representative examples of viruses currently used in clinical trials.

<u>Virus</u>	<u>Indication</u>	<u>Target/transgene</u>	<u>Mechanism of action</u>	<u>Reference</u>
<u>AdCD40L</u> <u>Adenoviridae</u>	<u>Chronic lymphocytic leukemia</u> <u>-Urinary bladder cancer</u>	<u>coxsackie adenoviral receptor/CD40L</u>	<u>Apoptosis of CD40<sup>+</sup> tumor cells and secondary immunostimulatory response</u>	<u>(Ullenhag, G. &amp; Loskog, A. S. I. 2012)</u>
<u>AAV2-hRPE65v2</u> <u>Parvoviridae</u>	<u>Congenital blindness</u>	<u>Ubiquitous receptors/RPE65</u>	<u>RPE65 gene function restoration</u>	<u>(Bennett, J., Ashtari, M., Wellman, J., Marshall, K. A., Cyckowski, L., L., Chung, D. C. et al. 2012)</u>
<u>Rexin-G</u> <u>Retroviridae</u>	<u>Pancreatic cancer</u>	<u>Collagen/ dominant negative cyclin G1 gene</u>	<u>Cell death by apoptosis after arresting at cell cycle G1 phase</u>	<u>(Chawla, S. P., Chua, V. S., Fernandez, L., Quon, D., Blackwelder, W. C., Gordon, E. M. et al. 2010)</u>

Código de campo cambiado

Código de campo cambiado

Código de campo cambiado

Con formato: Sangría: Izquierda: 0 cm, Derecha: 0 cm, Interlineado: sencillo